Healthcare Stocks In Spotlight (GALE, INCY, PPHM, ARNA)

Galena Biopharma Inc (NASDAQ:GALE) moved +5.21% higher to settle at $2.02 after paying $10M upfront to acquire the U.S. rights to a fast-acting drug Abstral designed to treat severe pain in cancer patients. The stock moved +94.23% up from the 52 week low and was -42.94% below the 52 week high.
Its latest closing price was +14.74% up from an average-price of 200 days while it kept its distance from the SMA 50 at +8.72% and +3.35% compared with the SMA 20. The 6-month performance of this stock stands at +8.60% with a gain of 6.32% in the last three months and +31.17% in the previous twelve months.

How Should Investors Trade GALE After Today’s Rally? Find Out Here

Incyte Corporation (NASDAQ:INCY) shares settled down -4.23% to $23.79, trading on above average volume after a regulatory filing disclosed that a patient had developed a case of progressive multifocal leukoencephalopathy, or PML, while taking its lead drug, Jakafi.
The stock, as of last close, traded +54.18% up from its 52 week low and was -9.54% behind its 52 week high. Its latest closing price was +20.50% above the SMA200 while the distance from SMA 50 and SMA 20 was +17.97% and +5.44% respectively. The stock has a 6-month performance of +30.93%.

Can INCY Recover After The Recent Fall? Find Out Here

Peregrine Pharmaceuticals (NASDAQ:PPHM) shares fell 2.90% to $1.34. The company, on Mar. 12, announced financial results for the third quarter ended January 31, 2013 of fiscal year (FY) 2013 and provided an update on its advancing clinical pipeline and other corporate developments.
Total revenues for the third quarter of FY 2013 were $7,039,000 compared to $3,281,000, for the same quarter of the prior fiscal year. The company’s consolidated net loss decreased 56% to $4,914,000, or $0.04 per basic and diluted share, for the third quarter of FY 2013, compared to a net loss of $11,090,000, or $0.13 per basic and diluted share, for the same quarter of the prior year.

Can PPHM Bounce Back? Find Out Here

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has reviewed its financial results for the 4th Q and fiscal year of 2012, and it has also provided a business update. Its revenues for the 4th quarter of 2012 remained $1.9 million, in comparison to the prior year 4th Q of $2.1 million. The revenues of Arena for the fiscal year of 2012 reported $27.6 million, versus the year ago of $12.7 million.
The company reported the decrease of -1.87% to close at $7.88 with the overall traded volume of 4.41 million shares. Its market capitalization was $1.71 billion. Its beta value stands at 0.14 times and earnings per share was $-0.53. Arena has the total of 217.29 million outstanding shares. Company’s year to date performance remained pessimistic with the drop of -12.64%. If we look at the last 6 months of trade, that is in the bearish zone with the tumble of -14.9%.

Should Investors Buy ARNA After The Recent Plunge? Find Out Here

Leave a Reply